Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 14/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532721 | 1.00 | HTR2A (0.39) | HTR2AHTR2CHTR2BEPAS1FNTA | |
| SCHEMBL15267245 | 1.00 | HTR2A (0.39) | HTR2AHTR2CHTR2BEPAS1FNTA | |
| SCHEMBL1424574 | 1.00 | HTR2A (0.39) | HTR2AHTR2CHTR2BEPAS1FNTA | |
| SCHEMBL30666726 | 0.89 | ACHE (0.43) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL14884984 | 0.88 | ACHE (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL30667065 | 0.88 | ACHE (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL13270953 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BEPAS1P2RX7 | |
| SCHEMBL12583743 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL8263257 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BEPAS1 | |
| SCHEMBL17768626 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019366-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2025-01-16 | — | — | US | claimed |
| CN-114380798-A | Salts of Pim kinase inhibitors | 因赛特公司 | 2022-04-22 | — | — | CN | claimed |
| US-20210155605-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2021-05-27 | — | — | US | claimed |
| US-20170121310-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2017-05-04 | — | — | US | claimed |
| EP-4695240-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12534475-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250019366-A1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2024215923-A2 | CYCLIC VINYL SULFONE WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12077546-B2 | Bicyclic pyridine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| EP-2203447-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2134691-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009118384-A1 | QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009037308-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037343-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009019274-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035379-A1 | BICYCLIC PYRIDINE DERIVATIVE | CBR1, CBR3, CYP2B6 | HTR2A 642/4885HTR2C 138/4885HTR2B 453/4885 |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | HTR2A 4536/4885HTR2C 4347/4885HTR2B 4580/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | HTR2A 4423/4885HTR2C 4302/4885HTR2B 4425/4885 |
| US-12077546-B2 | Bicyclic pyridine derivative | CBR1, CBR3, CYB5R3 | HTR2A 1075/4885HTR2C 428/4885HTR2B 304/4885 |
| US-20210155605-A1 | SALTS OF A PIM KINASE INHIBITOR | PIM1, PIM3, PIM2 | HTR2A 4423/4885HTR2C 3112/4885HTR2B 4040/4885 |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | HTR2A 1515/4885HTR2C 2169/4885HTR2B 1959/4885 |
| US-20250019366-A1 | SALTS OF A PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | HTR2A 4403/4885HTR2C 3100/4885HTR2B 4003/4885 |
| US-20170121310-A1 | SALTS OF A PIM KINASE INHIBITOR | PIM1, PIM3, PIM2 | HTR2A 4423/4885HTR2C 3112/4885HTR2B 4040/4885 |
| US-12534475-B2 | Bicyclic pyridine derivative | CBR1, CYP2B6, CBR3 | HTR2A 407/4885HTR2C 63/4885HTR2B 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.